HC Wainwright Reaffirms “Buy” Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $15.00 target price on the stock.

Femasys Price Performance

Shares of FEMY opened at $1.29 on Friday. The company’s 50-day moving average is $1.41 and its 200-day moving average is $1.23. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The firm has a market capitalization of $29.54 million, a PE ratio of -1.59 and a beta of -2.85. Femasys has a fifty-two week low of $0.86 and a fifty-two week high of $1.84.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $1.66 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. Equities analysts forecast that Femasys will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of Femasys by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock valued at $238,000 after acquiring an additional 9,681 shares during the period. Northern Trust Corp raised its stake in Femasys by 42.6% in the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares in the last quarter. Citadel Advisors LLC bought a new stake in Femasys in the 4th quarter valued at about $45,000. XTX Topco Ltd grew its position in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Femasys in the fourth quarter valued at approximately $30,000. 65.27% of the stock is owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.